Adherence to Guidelines for Hepatitis B, Pneumococcal, and Influenza Vaccination in Patients With Diabetes

Matthew J Alcusky, Jayne Pawasauskas, Matthew J Alcusky, Jayne Pawasauskas

Abstract

IN BRIEF This single-center, cross-sectional study was designed to assess adherence to national guidelines for the immunization of patients with diabetes and to evaluate predictors of vaccination with the hepatitis B, influenza, and 23-valent pneumococcal polysaccharide vaccines. In patients considered to be at increased risk for infection and infectious disease complications because of their history of diabetes, extensive nonadherence to immunization recommendations for all three vaccines was found. Nonadherence to the 2011 Advisory Committee on Immunization Practices' recommendation for hepatitis B vaccination was ubiquitous. Allocation of health care resources to increase vaccine coverage should remain a priority, with a focus on spreading awareness of the hepatitis B vaccine recommendation for people with diabetes.

References

    1. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003;26:510–513
    1. Muller LM, Gorter KJ, Hak E, et al. . Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005;41:281–288
    1. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med 1999;341:1906–1912
    1. Reilly ML, Poissant T, Vonderwahl CW, Gerard K, Murphy TV. Incidence of acute hepatitis B among adults with and without diabetes, 2009–2010 [Abstract]. Presented at the 49th annual meeting of the Infectious Disease Society of America and the HIV Medicine Association, Boston, Mass, 2011. Available from . Accessed 11 September 2013
    1. Housworth J, Langmuir AD. Excess mortality from epidemic influenza, 1957–1966. Am J Epidemiol 1974;100:40–48
    1. Bouter KP, Diepersloot RJ, van Romunde LK, et al. . Effect of epidemic influenza on ketoacidosis, pneumonia and death in diabetes mellitus: a hospital register survey of 1976–1979 in the Netherlands. Diabetes Res Clin Pract 1991;12:61–68
    1. Fedson DS, Chiarello LA. Previous hospital care and pneumococcal bacteremia: importance for pneumococcal immunization. Arch Intern Med 1983;143:885–889
    1. Finkelstein MS, Petkun WM, Freedman ML, Antopol SC. Pneumococcal bacteremia in adults: age-dependent differences in presentation and in outcome. J Am Geriatr Soc 1983;31:19–27
    1. Smith SA, Poland GA. Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care 2000;23:95–108
    1. Chandler PT, Chandler SD. Pathogenic carrier rate in diabetes mellitus. Am J Med Sci 1977;273:259–265
    1. Casey JI. Host defense abnormalities in diabetic patients. In Diabetes Mellitus. Vol. 5 Rifkin H, Raskin P, Eds. Bowie Md., Robert J. Brady Company , 1981, p. 219–223
    1. Beam TR Jr, Crigler ED, Goldman JK, Schiffman G. Antibody response to polyvalent pneumococcal polysaccharide vaccine in diabetics. JAMA 1980;244:2621–2624
    1. Schillie SF, Spradling PR, Murphy TV. Immune response of hepatitis B vaccine among persons with diabetes: a systematic review of the literature. Diabetes Care 2012;35:2690–2697
    1. Frasca D, Diaz A, Romero M, et al. . Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. Vaccine 2013;31:3603–3610
    1. Rodriguez-Blanco T, Vila-Corcoles A, de Diego C, et al. . Relationship between annual influenza vaccination and winter mortality in diabetic people over 65 years. Hum Vaccin Immunother 2012;8:363–370
    1. Wang IK, Lin CL, Chang YC, et al. . Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study. Vaccine 2013;31:718–724
    1. Shapiro ED, Berg AT, Austrian R, et al. . The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453–1460
    1. Centers for Disease Control and Prevention Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2013–2014. MMWR Recomm Rep 2013;62(RR-07):1–43
    1. Centers for Disease Control and Prevention Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012;61:816–819
    1. American Diabetes Association Standards of medical care in diabetes—2014. Diabetes Care 2014;37 (Suppl 1):S14–S80
    1. Centers for Disease Control and Prevention Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60:1709–1711
    1. Immunization and infectious diseases. Available from . Accessed 10 September 2013
    1. Centers for Disease Control and Prevention. Noninfluenza vaccination coverage among adults—United States , 2011. MMWR 2013;62:66–72
    1. Centers for Disease Control and Prevention Flu vaccination coverage. Available from . Accessed 14 January 2014
    1. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995;20:992–1000
    1. Mast EE, Weinbaum CM, Fiore AE, et al. ; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR 2006;55(RR-16):1–33
    1. Krueger P, St. Amant O, Loeb M. Predictors of pneumococcal vaccination among older adults with pneumonia: findings from the Community Acquired Pneumonia Impact Study. BMC Geriatr 2010;10:44:1–9
    1. Jackson LA, Baxter R, Naleway AL, Belongia EA, Baggs J. Patterns of pneumococcal vaccination and revaccination in elderly and non-elderly adults: a Vaccine Safety Datalink study. BMC Infect Dis 2009;9:37:1–7
    1. Healthy People : The Surgeon General’s Report on Health Promotion and Disease Prevention. Washington, D.C., U.S. Government Printing Office, 1979. (DHEW publ. no. PHS 79–55071)
    1. Centers for Disease Control and Prevention Influenza vaccination coverage trends (NHIS) 1989–2008. Available from . Accessed 14 January 2014
    1. Centers for Disease Control and Prevention Pneumococcal vaccination coverage trends (NHIS) 1989–2008. Available from . Accessed 14 January 2014
    1. Lu PJ, Santibanez TA, Williams WW, et al. ; Centers for Disease Control and Prevention. Surveillance of influenza vaccination coverage—United States, 2007–08 through 2011–12 influenza seasons. MMWR Surveill Summ 2013;62:1–28
    1. The Patient Protection and Affordable Care Act (PPACA) : Sec. 2713. Coverage of Preventive Health Services. Pub. L. No. 111-148, 124 Stat. 131, 2010 Available from . Accessed 9 September 2013
    1. Skelton JB; American Pharmacists Association ; Academy of Managed Care Pharmacy. Pharmacist-provided immunization compensation and recognition: white paper summarizing APhA/AMCP stakeholder meeting. J Am Pharm Assoc (2003) 2011;51:704–712
    1. American Pharmacists Association Types of vaccines that pharmacists are authorized to administer. Available from . Accessed 15 January 2014
    1. Slobodkin D, Zielske PG, Kitlas JL, McDermott MF, Miller S, Rydman R. Demonstration of the feasibility of emergency department immunization against influenza and pneumococcus. Ann Emerg Med 1998;32:537–543
    1. Rimple D, Weiss SJ, Brett M, Ernst AA. An emergency department-based vaccination program: overcoming the barriers for adults at high risk for vaccine-preventable diseases. Acad Emerg Med 2006;13:922–930
    1. McKibben LJ, Stange PV, Sneller VP, Strikas RA, Rodewald LE; Advisory Committee on Immunization Practices. Use of standing orders programs to increase adult vaccination rates. MMWR Recomm Rep 2000;49(RR-1):15–16

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe